Princeton-based Made Scientific on Monday announced it has been selected as the official manufacturing partner for Columbia University’s NOVAKnee program. The initiative aims to pioneer a first-in-class, living biologic alternative to traditional total knee replacements.
The high-profile collaboration supports an academic and clinical effort funded by the federal Advanced Research Projects Agency for Health. Specifically, the project operates under ARPA-H’s Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, which is tasked with developing next-generation treatments for joint disease.
Unlike standard mechanical joint surgeries that rely on synthetic components, the NOVAKnee implant represents a fundamental paradigm shift toward regenerative medicine.
The technology uses a advanced biodegradable scaffold seeded with both autologous (patient-derived) and allogeneic (donor-derived) bone and cartilage progenitor cells. Once implanted, the construct is designed to prompt natural tissue regeneration, effectively restoring joint function organically rather than substituting it with metal and plastic.
Under the terms of the agreement, Princeton-based Made Scientific will oversee:
- Technology Transfer: Porting the laboratory-scale engineering methods developed at Columbia into a scalable infrastructure.
- Process & Analytical Development: Standardizing the drug substance and drug product parameters required for cellular consistency.
- GMP Clinical Manufacturing: Producing the dual-component implants, designated NOVAKnee-T and NOVAKnee-L, for human use under current Good Manufacturing Practice standards.
The manufacturing pipeline is geared toward translating academic innovation into a regulated clinical environment under U.S. Food and Drug Administration (FDA) oversight. Human clinical trials are currently on the horizon.
“This program reflects a bold shift in orthopedic care by replacing a traditional implant with a living, cell-based product,” Syed Husain, chairman and CEO of Made Scientific said. “We are committed to delivering the manufacturing excellence required to advance NOVAKnee from the laboratory to patients.”
The underlying science stems from a cross-disciplinary team at Columbia University’s School of Engineering and the Vagelos College of Physicians and Surgeons, operating under a broader university initiative known as NOVAJoint.
“The NOVAKnee program aims to fundamentally change how we approach joint replacement, and a manufacturing partner with deep cell therapy expertise is essential to that goal,” Clark Hung, vice chair and professor of Biomedical Engineering at Columbia University said.
The NITRO program driving this development is spearheaded by ARPA-H Program Manager Dr. Ross Uhrich, focusing federal research resources on cellular therapies capable of scaling to meet widespread osteoarthritic demands.
